GSK plans to buy Canada#39;s Bellus Health for $2 billion to expand on respiratory therapies
The experimental drug- camlipixant, is at the heart of the deal, which is in late-stage development as a treatment for refractory chronic cough (RCC)
Latest News from Moneycontrol.com
Breaking News: National Junior College/Prep Football League Launches to Empower High School Athletes On and Off the Field











